upgrad overweight revisit base busi thesi
upgrad overweight neutral rais pt
wake lower court decis side freseniu effort termin
merger took closer look base gener busi base read
trend associ number notabl product well recent convers
manag pictur sustain ebitda emerg better
previous envis reflect signific contribut pipelin
reflect like meaning cost cut put anoth way annual ebitda
wors start realist view point
current ebitda reason particularli consid
numer gener compani view still covet akrx ophthalm capabl
take critic look ebitda though lost us ebitda declin
precipit sinc north declin around year
much function hand limited-competit product
brand-lik margin ultim face day reckon competit
perspect name inject ephedrin lidocain ointment topic clobetasol
taken togeth account half corpor ebitda estim
sure price eros portfolio whole fact life case
 gener portfolio though akrx focu primarili ophthalm inject
cushion compani kind commodit see
area gener space name oral solid note base iqvia
sale data three product cite declin combin versu
year-to-d ytd declin three product stand
ytd declin portfolio exclud asset stand per iqvia
larger point one could argu worst term major
pressur busi beyond product concentr longer problemat
asset account net sale see detail
cost structur assess assum lose appeal
resolut late manag strongli suggest
engag kind right-siz seen across gener space non-
oper margin declin larger
gener compani endo amneal certainli exposur
commod product run oper margin closer exclud
vasostrict key brand product respect unreason
expect cut spend combin cut low-
no-margin product reduc capac headcount impli oper margin
mid-to-high-teen ebitda north without sacrif much
top-lin
risk includ price pressur pressur competit entrant
focus primarili ophthalm inject gener product
price close octob
ep disc
debt total capit
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
item consid regard bullish view
thought cost structur look cost structur
transact freseniu announc april sg exclud non-
cash one-tim item respect oper
margin doubt reflect impact gener like inject ephedrin
brand-lik margin contrast sg
respect cost structur look similar would
impli ebitda north also assum year-over-year declin total
revenu big reach view assum manag get
even aggress cost cut mention cut low- no-margin
product trim capac someth standard practic past
coupl year among player
would overli concern increment pressur base
busi tie gener pipelin base gener
busi continu declin show sign stabil report
net revenu gener busi versu net sale
vast improv compar year-over-year declin
report respect signific portion eros
base busi attribut hand high-margin limited-competit
gener sinc encount signific competit price headwind
exampl sale lidocain ointment
declin per iqvia similarli sale topic clobetasol
product versu sale although product
continu show signific declin account far smaller portion
product concentr longer problemat manag made clear
product account net sale even among
current top seller caveat instanc akrx accutan gener
histor strong perform one larger contributor top-lin
said amneal enter accutan market februari though gener
quick garner meaning volum share juli
total volum isotretinoin product sinc experienc suppli issu
though comment extent issu surmis
resolv long note week end prescript
gener account overal volum compar volum share
week end period akrx product grew
week end week market
consist six gener includ akrx product presenc restrict
rem said akrx product share econom dougla pharmaceut
hold abbrevi nda file note margin lower corpor
margin put anoth way though accutan histor key contributor
would caution ascrib much import asset portion
page
would overli concern increment pressur base
busi tie gener pipelin akrx form topic
clobetasol still fairli meaning sale sale per iqvia account
overal iqvia-bas sale said alreadi crowd market
ten gener though one reason expect see price eros
would hard fathom eros sale percentag term anywher near
kind eros saw last year anoth consider would keep mind
extent modest-to-moder eros contribut new
approvals/launch even minor product cushion impact extent
bear mind pend abbrevi nda anda file
product file decatur il facil inject facil
troubl spot term observ account minor
file note around half pend anda somerset
nj facil primarili ophthalm decatur il facil half
amityvil ny facil facil acquir via high-tech acquisit
focus rang dosag form includ topic nasal spray liquid
semi-solid name outsourc pipelin gener well-
age even though prolif regard new anda
submiss sinc freseniu transact announc would necessarili
assum landscap term new approv barren next
restasi durezol anda clear wild card obviou caveat
rel complex ophthalm product yet see gener market
format regard restasi manag assert believ
among first gener compani file paragraph iv said
twelv month sinc feder district court rule four patent cover
allergan restasi invalid approv ab-rat gener
underscor complex associ product ophthalm
emuls extent part first wave approv margin least
initi somewhat decent provid competit initi limit around
durezol diflupredn like restasi also formul ophthalm emuls
sale last month per iqvia attract
opportun view given paragraph iv filer
patent surround product overturn result ipr inter part review
proceed late upheld feder appel court august
stay regard launch expir confirm
piv file januari provid yet window underli complex
product extent filer paragraph though
quantifi impact ostens higher-valu gener notori difficult would
unreason estim launch durezol gener exclus
could add increment ebitda year meaning cash
gener product beyond year given like limited-competit
market extend period
page
put anoth way two file keep eye term potenti driver
signific ebitda expans view underscor would strateg
interest ophthalm still one dosag form enough
complex widespread commodit someth yet see
think granular term simpli illustr purpos ad anoth
annual ebitda contribut restasi durezol gener
estim ebitda around cite includ cost save
point ebitda closer impli ev/ebitda
comp tabl gener group
price octob
compani report factset pjc research
thought valuat includ exclud akrx higher-valu
shots-on-go larger point current ebitda without reflect
pipelin reflect cost save around gener keep
multipl seen major gener compani ebitda teva
respect factor signific
contribut durezol potenti restasi akrx ev/ebitda closer
view paint pictur risk/reward profil skew upsid
consid numer ex-u gener compani look
expand presenc particularli relat complic dosag
form consid mid-siz compani certainli digest
compani look expand capabl
page
note differ current vs prior segment may attribut realign contribut estim per im sale number
consensu estim
compani report factset pjc research
rais pt
new pt base price-to-earnings ep
estim discount unchang two year
unchang new pt impli ebitda multipl reflect
limit declin associ base gener busi oper expens
save north annual new estim reflect signific
contribut pipelin notabl reflect contribut gener
restasi durezol note includ potenti impact one
product particularli durezol consid could exclus
opportun ebitda could north translat ebitda multipl
though lost us net debt total debt
cash translat net ebitda multipl near sustain
overal busi view point ampl abil chip away debt level
notabl refinance/push matur bear mind debt balanc come
due
page
million except per outstand ep exhibit
page
page
companyendoakornavadelsandozsalessharesalessharesalessharesalesshared aug akorn quarterli annual incom statement
million except ep
sale
sell gener administr
amort intang
incom loss tax
expens revenu
cog total revenu
sell gener administr
note report result throughout pjc number exclud estim non-cash one time relat expens stock base compens merger relat cost sg line item
histor may provid segment revenu inform estim actual may base pjc estim im data
exclud stock-bas compens expens acquisit relat cost
reflect adjust impair process
proprietari piper jaffray co octob
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
